Wave Life Sciences Ltd.

Wave Life Sciences Ltd.

WVENYSE / NASDAQHealthcareSmall cap

$2.56-$0.16 (-5.9%)

Last close · Data as of Nov 20, 2026

Market cap
$1.2B
Revenue
$42.7M
Net margin
-478.3%
ROCE
-41.6%

This period includes a one-day price step on 8 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Wave Life Sciences Ltd. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-25.1%
3M
-51.2%
6M
-58.6%
1Y
Hidden
5Y
Hidden
  • This period includes a one-day price step on 8 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

This period includes a one-day price step on 8 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$0.16 (-5.9%) from $2.72 to $2.56 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in WVE, bought on each weekday since 2021.

News & filings

What Wave Life Sciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 204 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue more than doubled a year on average over three years.
  • This period includes a one-day price step on 8 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

Read moreShow less

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Sector
Healthcare
Shares outstanding
187.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.2B
P/B
2.3x
EV / Sales
13.7x
P/S
27.4x
52-week high
Hidden
52-week low
Hidden

Profitability

Operating margin
-504.0%
Net margin
-478.3%
EBITDA margin
-483.3%
ROE
-39.4%
ROCE
-41.6%
ROA
-32.0%
Asset turnover
0.07

Growth

Revenue
$42.7M
Revenue growth, 1Y
-60.5%
Revenue CAGR, 3Y
127.1%
Net profit growth, 1Y
110.7%
Free cash flow
-$188.2M

Solvency

Current ratio
6.47
Debt / Equity
0.03
Debt / Assets
0.03
CFO / Net profit
0.92
Cash / Market cap
51.4%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$42.7M
Gross profit$42.7M
Operating expenses$258.1M
Research and development$182.8M
Selling, general and administrative$75.3M
Operating income-$215.4M
Interest and other$11.0M
Pretax income-$204.4M
Tax and other$0.00
Net income-$204.4M

Revenue and net profit

Revenue fell 60.5% in FY2025; net profit is the dashed line.

Wave Life Sciences Ltd. revenue and net profit by fiscal year
Wave Life Sciences Ltd. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$3.6M-$161.8M
FY2023$113.3M-$57.5M
FY2024$108.3M-$97.0M
FY2025$42.7M-$204.4M

Cash flows

FY2025: -$187.5M from operations, -$188.2M free after investment (dashed).

Wave Life Sciences Ltd. operating and free cash flow by fiscal year
Wave Life Sciences Ltd. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$127.8M-$129.1M
FY2023-$19.4M-$20.5M
FY2024-$151.0M-$152.0M
FY2025-$187.5M-$188.2M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$42.7M-60.5%1Y
EBITDA
-$206.5M
Net profit
-$204.4M
Cash from operations
-$187.5M
Free cash flow
-$188.2M
Revenue CAGR, 3Y
127.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$42.7M-$206.5M-$204.4M-$188.2M-39.4%-60.5%+110.7%

Monthly returns

Month-by-month returns of WVE across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$638.5M
Liabilities$120.1M
Equity$518.4M
Paid-in capital$228.4M
Retained earnings-$1.3B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; WVE highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Wave Life Sciences Ltd. (this company)13.7x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Wave Life Sciences Ltd.WVEthis company$1.2B—2.3x-39.4%—
IRADIMED CORPORATIONIRMD$1.2B53.2x12.6x23.8%41.9x
CareDx, Inc.CDNA$1.2B-55.9x3.9x-7.0%-248.1x
Kestra Medical Technologies, Ltd.KMTS$1.2B-10.5x5.8x-55.4%-10.2x
AMN Healthcare Services, Inc.AMN$1.2B—1.8x-14.9%19.3x
Schrödinger, Inc.SDGR$1.2B-11.5x3.3x-28.4%-6.6x
Avanos Medical, Inc.AVNS$1.2B—1.5x-9.4%—
Zenas BioPharma, Inc.ZBIO$1.2B-3.1x4.8x-156.0%-2.8x
Absci CorporationABSI$1.1B-9.9x6.0x-60.8%-10.9x
Peer median—-10.2x4.4x-21.6%-6.6x

Year-to-date ROI

WVE since 1 January, against earlier years.

Historical volatility

WVE's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Wave Life Sciences Ltd. operating margin by fiscal year
Wave Life Sciences Ltd. operating margin by fiscal year
DateOperating margin
FY2022-4458.1%
FY2023-60.0%
FY2024-101.9%
FY2025-504.0%
LineFY2025
Operating expensesOperating Expense$258.1M
Research and developmentResearch And Development$182.8M
Total expensesTotal Expenses$258.1M
Pretax incomePretax Income-$204.4M

Learn while you research

Academy chapters picked for Wave Life Sciences Ltd. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →